New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 17, 2014
04:55 EDTMRGE, MRGE, KND, KND, IMMU, IMMU, COO, COO, CVS, CVS, ARNA, ARNA, GMED, GMED, ISIS, ISIS, Q, Q, STML, STML, BDSI, BDSI, DEPO, DEPOWells Fargo to hold a conference
2014 Healthcare Conference to be held in Boston on June 17-18.
News For MRGE;BDSI;STML;Q;ISIS;GMED;ARNA;CVS;COO;IMMU;KND;DEPO From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
September 26, 2014
13:53 EDTCVSCVS' Caremark to pay $6M to settle false claims allegations
Subscribe for More Information
10:01 EDTISISOn The Fly: Analyst Initiation Summary
Subscribe for More Information
09:30 EDTBDSIBioDelivery Sciences management to meet with Summer Street
Subscribe for More Information
08:48 EDTIMMUImmunomedics publishes results on (E1)-3s
Subscribe for More Information
07:32 EDTARNABioCentury to hold a conference
21st Annual NewsMakers in the Biotech Industry Conference to be held in New York on September 26.
07:20 EDTISISIsis Pharmaceuticals assumed with a Market Perform at Leerink
Subscribe for More Information
September 25, 2014
10:06 EDTCVSCVS Health management to meet with Leerink
Meeting to be held in Los Angeles on October 1 hosted by Leerink.
08:59 EDTISISSummer Street chief scientific officer holds an analyst/industry conference call
Subscribe for More Information
September 24, 2014
08:33 EDTCVSCVS Health enters into clinical affilitation with three academic medical centers
CVS Health has entered into new clinical affiliations with three leading academic medical centers. The collaborating medical centers include the University of Maryland Medical System, University of Texas Medical Branch at Galveston, and the University of Alabama at Birmingham Health System. Through these clinical affiliations the patients served by these medical centers will continue to have access to clinical support, medication counseling, chronic disease monitoring and wellness programs at CVS/pharmacy stores and MinuteClinic, the retail medical clinic division of CVS Health.
September 23, 2014
10:33 EDTCVSCVS Health management to meet with Wolfe Research
Subscribe for More Information
10:02 EDTIMMUOn The Fly: Analyst Initiation Summary
Subscribe for More Information
07:54 EDTMRGELeerink to hold a conference
Subscribe for More Information
06:03 EDTIMMUImmunomedics initiated with a Buy at Jefferies
Subscribe for More Information
September 22, 2014
15:14 EDTISISIsis Pharmaceuticals management to meet with JPMorgan
Meeting to be held in Los Angeles on September 22 hosted by JPMorgan.
September 19, 2014
07:22 EDTCVSNational Press Club holds a luncheon meeting
Subscribe for More Information
September 18, 2014
11:55 EDTCVSRite Aid falls as drugstore chain trims FY15 view
Subscribe for More Information
September 17, 2014
16:18 EDTDEPODepomed says FDA recognizing 7 years orphan-drug exclusivity for Gralise in PHN
Depomed (DEPO) disclosed in a filing that on September 16 the company received a letter from the FDA informing the company that pursuant to the order issued on September 5 by a judge of the U.S. District Court for the District of Columbia, the FDA is recognizing seven years of orphan-drug exclusive approval for the company’s Gralise for the management of postherpetic neuralgia. The letter also confirms the FDA will not approve any abbreviated New Drug Application referencing Gralise during the period of orphan-drug exclusive approval, which began on January 28, 2011. The FDA has 60 days after issuance of the order in Depomed, Inc. v. HHS to file a notice appealing the order to the United States Court of Appeals for the Federal Circuit. The period of orphan drug exclusivity applicable to Gralise for PHN is separate from marketing exclusivity arising from the previously disclosed decision issued on August 19 in the company’s patent litigation lawsuit against Actavis (ACT) related to an ANDA filed by Actavis seeking to market generic versions of Gralise. The decision found that Actavis infringed all seven of the company’s patents asserted in the litigation, upheld the validity of the patents and enjoined FDA approval of the Actavis ANDA until February 26, 2024, the latest expiration date of the infringed patents. On September 15, Actavis filed a notice appealing the decision to the United States Court of Appeals for the Federal Circuit, Depomed stated. Previously disclosed settlement agreements between the Company and two other Gralise ANDA filers permit the sale of generic Gralise beginning on January 1, 2024.
08:44 EDTBDSIBioDelivery Sciences remains takeout candidate for Endo, says Summer Street
Summer Street believes a potential takeover of BioDelivery Sciences (BDSI) by partner Endo (ENDP) is no less likely after Endo made a bid to acquire Auxilium (AUXL). The firm believes an Endo buyout of BioDelivery is likely a 2015 event when BioDelivery's Bunavail for opioid dependence is on the market and BEMA Buprenorphine is facing FDA approval. Summer Street says it is a buyer of BioDelivery Sciences on weakness this morning and keeps a Buy rating on the name with a $28 price target.
07:43 EDTARNABofA/Merrill to hold a conference
Subscribe for More Information
07:29 EDTISISIsis Pharmaceuticals earns $4M from Achaogen for Phase 3 study of plazomicin
Subscribe for More Information
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use